公开(公告)号：US20230404924A1

公开(公告)日：2023-12-21

申请号：US18118479

申请日：2023-03-07

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Takumi Asada ,  Gerald R. Galluppi ,  Seth Cabot Hopkins ,  Megumi Maruyama ,  Siriporn Toongsuwan ,  Yuki Tsushima

IPC: A61K9/20 ,  A61P25/18 ,  A61K31/40 ,  A61K47/38 ,  A61P25/24

CPC classification number: A61K9/2054 ,  A61P25/18 ,  A61K31/40 ,  A61K47/38 ,  A61P25/24

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US20220339392A1

公开(公告)日：2022-10-27

申请号：US17860454

申请日：2022-07-08

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Michael Segal ,  Nathan Arian Abel ,  Spencer Brown ,  Everett Crosland ,  Francisco Javier de Ana Arbeloa ,  Thomas Goodin ,  Joseph Gordon ,  Michael Metz ,  Daniel James Nelson ,  Jae Hong Park ,  Sean Scanlon ,  Janis Paulis Skujins ,  Jennet Toyjanova

IPC: A61M16/14 ,  G01F1/34 ,  A61M16/00 ,  G01K13/20

Abstract: Described herein are devices, systems and methods for monitoring the use of a nebulized medication, such as can be administered using a nebulizer. These can be used for monitoring a patient undergoing treatment for COPD and improve compliance to the recommended therapy. Monitored parameters include flow, humidity and acceleration and provide data as to the quantity and quality of nebulizer use.

公开(公告)号：US11440921B2

公开(公告)日：2022-09-13

申请号：US17006101

申请日：2020-08-28

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Andrea Bauer ,  Nandkumar Nivritti Bhogle ,  Xiaoxia Chen ,  Shahla Jamzad ,  Robert Joseph Prytko ,  Kostas Saranteas ,  Michael Joseph Sizensky ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D495/04 ,  A61K9/20 ,  A61K45/06 ,  A61K31/381 ,  A61P25/18 ,  A61P25/00

Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

公开(公告)号：US20220241156A1

公开(公告)日：2022-08-04

申请号：US17622046

申请日：2020-06-26

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Thierry BILBAULT ,  Arthur TONG

IPC: A61J7/00 ,  A61K9/70 ,  A61J1/00 ,  B65D50/00

Abstract: Product containers, especially child-resistant product dispensers, and methods of use thereof. In some particular embodiments, provided herein are child-resistant medication dispensers, and methods of use thereof for administering medications to individuals that may suffer from manual dexterity problems. The disclosure is particularly useful in dispensing orally dissolving medications intended for sublingual application, such as orally dissolving strips. In one embodiment of the disclosure a medication dispenser is disclosed comprising a container having an opening and an inner chamber, a cap configured to close the opening of the container and provide a child-resistant locking engagement with the container, and a tray deployable in the chamber of the container and configured to hold at least one pouch carrying a dose of medication. The tray can include a support configured to hold one or more pouches when the tray and pouches are deployed within the container.

公开(公告)号：US20210315859A1

公开(公告)日：2021-10-14

申请号：US17228796

申请日：2021-04-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Carrie A. BOWEN ,  Seth Cabot HOPKINS ,  Colleen M. SYNAN

IPC: A61K31/381 ,  A61P25/18

Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11136304B2

公开(公告)日：2021-10-05

申请号：US16817749

申请日：2020-03-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nandkumar Nivritti Bhogle ,  Takahiko Hashizuka ,  Robert Joseph Prytko ,  John R. Snoonian ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D311/76

Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

公开(公告)号：US20210093606A1

公开(公告)日：2021-04-01

申请号：US16991771

申请日：2020-08-12

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Carrie A. Bowen ,  Douglas F. Burdi ,  Michele L. R. Heffernan ,  Lee W. Herman ,  Linghong Xie

IPC: A61K31/352 ,  C07D413/04 ,  C07D417/04 ,  C07D405/04 ,  A61P25/28 ,  A61P25/24 ,  A61P25/08 ,  A61P25/16 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/42 ,  A61K31/427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/506

Abstract: Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.

公开(公告)号：US20210061759A1

公开(公告)日：2021-03-04

申请号：US16994835

申请日：2020-08-17

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D207/09

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

公开(公告)号：US20210046021A1

公开(公告)日：2021-02-18

申请号：US16890002

申请日：2020-06-02

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Thomas JERUSSI ,  Qun Kevin FANG ,  Mark G. CURRIE

IPC: A61K31/135 ,  C07C211/42

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

公开(公告)号：US20200277286A1

公开(公告)日：2020-09-03

申请号：US16722048

申请日：2019-12-20

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John Emmerson CAMPBELL ,  Una CAMPBELL ,  Taleen G. HANANIA ,  Liming SHAO

IPC: C07D409/04 ,  C07D409/14 ,  C07D491/048 ,  C07D495/04 ,  C07D405/04

Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.